Capital International Ltd. CA Has $18.29 Million Holdings in Boston Scientific Co. (NYSE:BSX)

Capital International Ltd. CA boosted its stake in Boston Scientific Co. (NYSE:BSX) by 93.0% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 204,736 shares of the medical equipment provider’s stock after buying an additional 98,646 shares during the period. Capital International Ltd. CA’s holdings in Boston Scientific were worth $18,287,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. TFC Financial Management Inc. boosted its stake in shares of Boston Scientific by 308.8% in the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 210 shares in the last quarter. Global Wealth Strategies & Associates lifted its holdings in Boston Scientific by 423.7% during the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 250 shares during the last quarter. West Oak Capital LLC acquired a new position in Boston Scientific in the fourth quarter valued at about $29,000. Valley National Advisers Inc. grew its stake in Boston Scientific by 262.4% during the fourth quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 286 shares during the last quarter. Finally, Fairway Wealth LLC acquired a new stake in shares of Boston Scientific during the fourth quarter worth approximately $36,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $95.08 on Friday. Boston Scientific Co. has a fifty-two week low of $66.80 and a fifty-two week high of $107.17. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The company has a market capitalization of $140.63 billion, a price-to-earnings ratio of 76.06, a P/E/G ratio of 2.79 and a beta of 0.73. The firm’s 50 day simple moving average is $99.68 and its 200 day simple moving average is $94.26.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. As a group, sell-side analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the sale, the executive vice president now directly owns 5,502 shares in the company, valued at $560,103.60. This trade represents a 75.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the business’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $104.25, for a total value of $487,368.75. Following the completion of the sale, the executive vice president now owns 28,454 shares in the company, valued at approximately $2,966,329.50. This trade represents a 14.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 133,183 shares of company stock worth $13,948,476. Company insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on BSX shares. Wells Fargo & Company boosted their target price on Boston Scientific from $100.00 to $118.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Truist Financial decreased their target price on Boston Scientific from $120.00 to $113.00 and set a “buy” rating on the stock in a report on Friday, April 11th. Royal Bank of Canada raised their target price on Boston Scientific from $105.00 to $116.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Needham & Company LLC upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $113.00 price target on the stock in a research report on Wednesday. Finally, Argus set a $130.00 price objective on shares of Boston Scientific in a research report on Tuesday, February 18th. One research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $110.22.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.